Trial · NCT02982005
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
NCT02982005, Phase 3, Completed, Kyowa Kirin Korea Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea. Trials, record NCT02982005. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02982005
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
- NCT number
- NCT02982005
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 62 participants, actual
- Lead sponsor
- Kyowa Kirin Korea Co., Ltd.
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- KHK4827, Placebo
- First posted
- 2016-12-05
- Last updated
- 2024-04-29
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Psoriasis area and severity index (PASI) 75 response | at week 12 | |
| Primary | Static physician's global assessment (sPGA) of "0 (clear)" or "1 (almost clear)" | at week 12 | |
| Secondary | PASI 50/75/90/100 response by visit | Baseline to week 64 | |
| Secondary | sPGA of "0 (clear) or 1 (almost clear)" by visit | Baseline to week 64 | |
| Secondary | Body surface area (BSA) involvement of lesion | Baseline to week 64 | |
| Secondary | Nail psoriasis severity index (NAPSI) score (applicable only to subjects who had nail symptoms at baseline) | Baseline to week 64 | |
| Secondary | Psoriasis scalp severity index (PSSI) score (applicable only to subjects who had scalp symptoms at baseline) | Baseline to week 64 | |
| Secondary | Dermatology life quality index (DLQI) | Baseline to week 64 | |
| Secondary | Treatment-emergent adverse events (TEAEs) or drug-related TEAEs | Baseline to week 64 | |
| Secondary | Laboratory values | Baseline to week 64 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02982005
GET https://conductscience.org/api/trials/v1/NCT02982005/registered